Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute is seeking to support the Canine Cancer Immunotherapy Network (K9CIN) through five U01 awards to advance cancer immunotherapy trials in pet dogs. Because canine cancers develop spontaneously and mirror human disease progression, these trials provide critical preclinical data on immune responses and the efficacy of novel or repurposed drugs. The initiative aims to maintain momentum in developing canine analytics and therapeutics, offering cutting-edge treatments to pet dogs while generating translatable data for human medical applications. The funding structure consists of one multifunctional Network Coordinating Center responsible for network facilitation and limited research, and four separate awards dedicated to conducting clinical trials using immunotherapeutic agents alone or in combination with other modalities. This consolidated opportunity streamlines previous funding paths to support the evaluation of treatment dosing, sequencing, and correlative studies.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The goal of this RFA is to continue to support canine cancer immunotherapy clinical trials as indicators of safe and effective cancer treatments in humans. Pet dog patients develop cancer spontaneously and the courses of disease and treatment responses are similar to those in humans. Canine clinical trial results are translatable to humans. The assessment of responses to immunotherapy in immune-intact animals with existing cancers, such as pet dog patients, is the only way to preclinically take into account all facets of the immune response to cancer and to therapies. Ethically, pet dogs can benefit from the clinical trials by receiving cutting-edge therapies supported by the NIH, while providing important data informative to human disease. The network supported by this U01 RFA will consist of five U01 awards. One U01 will serve as a multifunctional Network Coordinating Center that will not only facilitate coordination across the Canine Cancer Immunotherapy Network (K9CIN) but will also perform limited research to support the network. Four U01 recipients will conduct canine clinical trials using immunotherapeutic agents alone or in combination with other treatment modalities.
Through this reissue Notice of Funding Opportunity, the National Cancer Institute intends to continue to support canine immunotherapeutic development as the field continues to grow, in part because of NIH funding. In the last five years, canine immunotherapeutics such as immune checkpoint inhibitors have become available as have canine analytics, development of which were partially supported by NCI. The goal is to maintain the momentum for further development of canine analytics and therapeutics and the ability to evaluate novel and repurposed drugs, treatment combinations, and treatment dosing and sequencing in pet dogs in a timely fashion. This NOFO consolidates the prior U01 (RFA-CA-21-050) and U24 (RFA-CA-21-051) funding opportunities to streamline the application process for continued support to K9CIN. Applicants have the option of submitting either for the Network Coordinating Center with limited research focus or for conducting canine cancer immunotherapy clinical trials and correlative studies. These important canine cancer-related activities will provide a valuable opportunity for NIH support to benefit humans and dogs, at both ends of the leash.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
